Lixisenatide is a daily injection. It is no longer available in the U.S. [14] Adlyxin: Name-brand version of Lixisenatide ...

Third quarter, 2024 total revenues grew 11% to $3.72 billion, primarily driven by higher Sanofi collaboration ... slower after a single EYLEA HD injection at week 96, as compared to these patients ...

Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring ... the weekly injections and easy-to-use injection pens have made weight-loss drugs more ...

Janel Wright had just days left in her insulin supply in early January when a pharmacist told her there was none of the drug left to fill her prescription. Her neighborhood Fred Meyer pharmacy in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi ...